SERA PROGNOSTICS, INC. Selling and Marketing Expense
SERA PROGNOSTICS, INC. (SERA) reported Selling and Marketing Expense of $2.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-12
- SERA PROGNOSTICS, INC. selling and marketing expense for the quarter ending 2026-06-30 was $2.24M, a 23.17% increase year-over-year.
- SERA PROGNOSTICS, INC. selling and marketing expense for the quarter ending 2026-03-31 was $2.01M, a 36.87% increase year-over-year.
- SERA PROGNOSTICS, INC. selling and marketing expense for the quarter ending 2025-12-31 was $1.67M, a 26.46% decline year-over-year.
- SERA PROGNOSTICS, INC. selling and marketing expense for the quarter ending 2025-09-30 was $1.59M, a 34.80% increase year-over-year.
- SERA PROGNOSTICS, INC. selling and marketing expense for fiscal 2025 was $6.55M, a 13.46% increase from fiscal 2024.
- SERA PROGNOSTICS, INC. selling and marketing expense for fiscal 2024 was $5.77M, a 30.88% decline from fiscal 2023.
- SERA PROGNOSTICS, INC. selling and marketing expense for fiscal 2023 was $8.35M, a 43.20% decline from fiscal 2022.
- SERA PROGNOSTICS, INC. selling and marketing expense for fiscal 2022 was $14.70M, a 42.32% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.24M 10-Q · filed 2026-08-12 | $4.25M 10-Q · filed 2026-08-12 | $5.92M derived: sum of 3 quarters · filed 2026-08-12 | $7.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.01M 10-Q · filed 2026-05-06 | $3.68M derived: sum of 2 quarters · filed 2026-05-06 | $5.27M derived: sum of 3 quarters · filed 2026-05-06 | $7.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $3.26M derived: sum of 2 quarters · filed 2026-03-18 | $5.08M derived: sum of 3 quarters · filed 2026-08-12 | $6.55M 10-K · filed 2026-03-18 |
| 2025-09-30 | $1.59M 10-Q · filed 2025-11-13 | $3.41M derived: sum of 2 quarters · filed 2026-08-12 | $4.88M 10-Q · filed 2025-11-13 | $7.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.82M 10-Q · filed 2026-08-12 | $3.29M 10-Q · filed 2026-08-12 | $5.55M derived: sum of 3 quarters · filed 2026-08-12 | $6.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.47M 10-Q · filed 2026-05-06 | $3.73M derived: sum of 2 quarters · filed 2026-05-06 | $4.92M derived: sum of 3 quarters · filed 2026-05-06 | $6.01M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $3.44M derived: sum of 2 quarters · filed 2026-03-18 | $4.54M derived: sum of 3 quarters · filed 2026-03-18 | $5.77M 10-K · filed 2026-03-18 |
| 2024-09-30 | $1.18M 10-Q · filed 2025-11-13 | $2.28M derived: sum of 2 quarters · filed 2025-11-13 | $3.51M 10-Q · filed 2025-11-13 | $4.81M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.10M 10-Q · filed 2025-08-06 | $2.33M 10-Q · filed 2025-08-06 | $3.63M derived: sum of 3 quarters · filed 2025-08-06 | $4.99M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.23M 10-Q · filed 2025-05-07 | $2.53M derived: sum of 2 quarters · filed 2025-05-07 | $3.89M derived: sum of 3 quarters · filed 2025-05-07 | $6.76M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $2.66M derived: sum of 2 quarters · filed 2025-03-19 | $5.53M derived: sum of 3 quarters · filed 2025-03-19 | $8.35M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.35M 10-Q · filed 2024-11-06 | $4.23M derived: sum of 2 quarters · filed 2024-11-06 | $7.04M 10-Q · filed 2024-11-06 | $10.10M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.87M 10-Q · filed 2024-08-07 | $5.69M 10-Q · filed 2024-08-07 | $8.74M derived: sum of 3 quarters · filed 2024-08-07 | $11.71M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $2.82M 10-Q · filed 2024-05-08 | $5.87M derived: sum of 2 quarters · filed 2024-05-08 | $8.84M derived: sum of 3 quarters · filed 2024-05-08 | $13.06M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $6.02M derived: sum of 2 quarters · filed 2024-03-20 | $10.24M derived: sum of 3 quarters · filed 2024-03-20 | $14.70M 10-K · filed 2024-03-20 |
| 2022-09-30 | $2.97M 10-Q · filed 2023-11-08 | $7.19M derived: sum of 2 quarters · filed 2023-11-08 | $11.64M 10-Q · filed 2023-11-08 | $16.19M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $4.22M 10-Q · filed 2023-08-09 | $8.68M 10-Q · filed 2023-08-09 | $13.22M derived: sum of 3 quarters · filed 2023-08-09 | $15.91M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $4.46M 10-Q · filed 2023-05-10 | $9.01M derived: sum of 2 quarters · filed 2023-05-10 | $11.70M derived: sum of 3 quarters · filed 2023-05-10 | $13.44M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $7.24M derived: sum of 2 quarters · filed 2023-03-22 | $8.98M derived: sum of 3 quarters · filed 2023-03-22 | $10.33M 10-K · filed 2023-03-22 |
| 2021-09-30 | $2.69M 10-Q · filed 2022-11-09 | $4.43M derived: sum of 2 quarters · filed 2022-11-09 | $5.78M 10-Q · filed 2022-11-09 | $6.79M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.74M 10-Q · filed 2022-08-10 | $3.09M 10-Q · filed 2022-08-10 | $4.10M derived: sum of 3 quarters · filed 2022-08-10 | $5.16M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.35M 10-Q · filed 2022-05-10 | $2.36M derived: sum of 2 quarters · filed 2022-05-10 | $3.42M derived: sum of 3 quarters · filed 2022-05-10 | $4.13M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $2.06M derived: sum of 2 quarters · filed 2022-03-29 | $2.78M derived: sum of 3 quarters · filed 2022-03-29 | $3.65M 10-K · filed 2022-03-29 |
| 2020-09-30 | $1.05M 10-Q · filed 2021-11-09 | $1.77M derived: sum of 2 quarters · filed 2021-11-09 | $2.63M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $712.00K 10-Q · filed 2021-08-30 | $1.58M 10-Q · filed 2021-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |